Strattera
Light
Studies Summary
🧠
Monitoring Behavioral Changes During Strattera Treatment
Behavioral changes should be monitored during Strattera treatment, especially in children and teens. Key signs include mood shifts, agitation, and depression.
⚠️
Boxed Warning: Suicidal Ideation
Strattera includes a warning for suicidal ideation, mostly affecting children and teens. Increased monitoring and proactive communication are required.
🩺
Emergence of New Psychiatric Symptoms
Strattera may cause new psychiatric symptoms like psychosis and mania, particularly in young patients during early treatment or dosage changes.
Highly Cited Studies
Long term Effects of Methylphenidate in Adults
Peer Reviewed Study 1
Strattera's Effectiveness in Adolescents with ADHD and Depression
Peer Reviewed Study 2
Strattera's Impact on Depression and Related Safety Concerns
Background: Monitoring Behavioral Changes During Strattera Treatment
Monitoring behavior during Strattera treatment is important, particularly in children and adolescents. Sudden changes in mood, increased agitation, or signs of depression should be carefully observed. Families and caregivers should be aware of these potential changes, especially during the initial months of treatment or when doses are adjusted.
Report any observed changes to healthcare providers promptly, as Strattera has been associated with serious psychiatric symptoms in some patients.
Report any observed changes to healthcare providers promptly, as Strattera has been associated with serious psychiatric symptoms in some patients.
“
Source Quotes:
Pediatric patients being treated with STRATTERA should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.,Families and caregivers of pediatric patients being treated with STRATTERA should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to healthcare providers.
Children and adolescents who start on atomoxetine require close monitoring for suicidal ideation and unusual changes in behavior.
Background: Strattera's Boxed Warning: Suicidal Ideation and Depression
Strattera carries a boxed warning for suicidal ideation, especially in children and adolescents. Clinical trials have shown an increase in suicidal thoughts among young patients treated with Strattera compared to those given a placebo. This highlights the need for ongoing communication between healthcare providers, patients, and families.
“
Source Quotes:
STRATTERA increased the risk of suicidal ideation in short-term studies in children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD).,The average risk of suicidal ideation in patients receiving STRATTERA was 0.4% (5/1357 patients), compared to none in placebo-treated patients.,In a pooled analysis of clinical trial data, it was observed that 7% of poor metabolizers (PMs) experienced depression compared to 4% of extensive metabolizers (EMs).
An analysis of multiple short-term trials revealed increased suicidal ideation in children and adolescents treated with atomoxetine (0.4%) compared to those treated with a placebo (0%).
Background: Strattera and New Psychiatric Symptoms
Strattera treatment can sometimes lead to the emergence of new psychiatric symptoms, particularly in children and adolescents. These symptoms may include psychosis, mania, or other severe mental health issues. Monitoring for these symptoms is important, especially during the early stages of treatment or when doses are adjusted.
While Strattera is effective for ADHD, being aware of these potential risks helps ensure the safety and well-being of those undergoing treatment.
While Strattera is effective for ADHD, being aware of these potential risks helps ensure the safety and well-being of those undergoing treatment.
“
Source Quotes:
New mental (psychiatric) problems in children and teenagers: new psychotic symptoms (such as hearing voices, believing things that are not true, being suspicious).,Monitor for emergence of bipolar disorder/hypomania while the patient is on atomoxetine.
Aggressive behavior or hostility, and the emergence of psychosis or mania may be associated with treatment with atomoxetine.
Peer Reviewed Study
Study: Strattera's Effectiveness in Adolescents with ADHD and Depression
This study examined the effects of Strattera (atomoxetine) in adolescents with both ADHD and major depressive disorder (MDD). While Strattera significantly improved ADHD symptoms compared to placebo, it did not show a significant difference in improving depressive symptoms. Both groups had similar rates of treatment-emergent mania, and no suicidal ideation or behavior was reported.
The findings suggest Strattera is effective for ADHD in this group but does not provide evidence for treating depression.
The findings suggest Strattera is effective for ADHD in this group but does not provide evidence for treating depression.
author
Atomoxetine ADHD and Comorbid MDD Study Group, Bangs ME, Emslie GJ, Spencer TJ, Ramsey JL, Carlson C, Bartky EJ, Busner J, Duesenberg DA, Harshawat P, Kaplan SL, Quintana H, Allen AJ, Sumner CR
journal
J Child Adolesc Psychopharmacol
Date Published
2007 Aug
Peer Reviewed Study
Study: Strattera's Impact on Depression and Related Safety Concerns
The abstract reviews key safety topics for atomoxetine, including its effects on suicidality, aggression, and psychosis. It reports no significant association between atomoxetine and suicidality, with a hazard ratio of 0.96 for suicide-related events. Symptoms of psychosis and mania mainly occurred in patients with comorbid bipolar disorder or depression, suggesting a potential interaction. The data also indicates no strong link between atomoxetine and aggression.
While cardiovascular effects were noted, they were not considered clinically significant in most patients, and decreases in growth appeared reversible over time.
While cardiovascular effects were noted, they were not considered clinically significant in most patients, and decreases in growth appeared reversible over time.
author
Reed VA, Buitelaar JK, Anand E, Day KA, Treuer T, Upadhyaya HP, Coghill DR, Kryzhanovskaya LA, Savill NC
journal
CNS Drugs
Date Published
2016 Jul
Key Takeaways
Conclusions
Studies show that while Strattera is effective for managing ADHD symptoms in adolescents, it doesn't significantly improve depression. This raises important considerations for its use in patients with comorbid conditions, particularly as Strattera has been associated with psychiatric risks like suicidal ideation and new psychiatric symptoms.
Evidence Summary
Long-Term Effects of Strattera: Attention, Side Effects, and Symptom Improvement
Three studies explore Strattera's long-term impact, focusing on its effects on attention and behavior, side effects over several years, and overall effectiveness in symptom improvement. Each study provides insights into different aspects of Strattera's performance over time, offering a comprehensive look at its sustained impact.
The findings reveal how Strattera influences attention, behavior, and overall symptom management across extended periods of use.
The findings reveal how Strattera influences attention, behavior, and overall symptom management across extended periods of use.
Evidence Summary
Comparing Adderall and Strattera in ADHD Treatment for Adults
Adderall and Strattera are both used to treat ADHD in adults, but they work differently. Adderall, a stimulant, and Strattera, a non-stimulant, have distinct effects that can vary between individuals.
This comparison highlights the differences in effectiveness and side effects, emphasizing how each medication may suit different people based on their unique responses.
This comparison highlights the differences in effectiveness and side effects, emphasizing how each medication may suit different people based on their unique responses.
Evidence Summary
Strattera's Impact on Sleep Patterns and Side Effects
Strattera can influence sleep patterns, as researchers tracked sleep changes in participants using the medication. Potential sleep-related side effects were noted, providing insights into how Strattera may impact rest.
The study’s findings highlight changes in sleep among those on Strattera, raising questions about its effects on sleep quality and duration. These observed changes may contribute to broader discussions about Strattera’s overall impact on daily life.
The study’s findings highlight changes in sleep among those on Strattera, raising questions about its effects on sleep quality and duration. These observed changes may contribute to broader discussions about Strattera’s overall impact on daily life.
